Japan Pharmaceuticals ASCO Trial Updates

This report summarizes 2026 ASCO abstract data for Japanese pharmaceuticals, highlighting positive clinical progress for Ono's ONO-4578 in gastric cancer and Takeda's TAK-928 in lung cancer.

Key Takeaways

• 1.Ono Pharmaceutical's ONO-4578 Phase 2 trial for gastric cancer showed significant improvements in PFS, OS, and ORR when combined with nivolumab and chemotherapy.
• 2.Takeda Pharmaceutical's IBI363 (TAK-928) demonstrated solid efficacy in early-phase trials for both first-line and IO-resistant non-small cell lung cancer (NSCLC).
• 3.Daiichi Sankyo's Datroway pipeline faces competition from Merck/Kelun's Sac-TMT, though Datroway may offer differentiation in safety and convenience.

Table of Contents

• Ono Pharmaceutical (4528.T): Phase 2 trial of ONO-4578
• Takeda Pharmaceutical (4502.T): Phase 1 trial of IBI363 (TAK-928)
• Daiichi Sankyo (4568.T): Implications from competitor data for Datroway
• Price Target Risks and Methodology - Takeda Pharmaceutical
• Price Target Risks and Methodology - Ono Pharmaceutical
• Price Target Risks and Methodology - Daiichi Sankyo

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial